The RGH E-Bulletin for this week
looks at the use of everolimus for
the estimated 220,000 Australian
women with HER2+ breast cancer.
The bulletin refers to the
BOLERO-2 study which in 2012
evaluated the efficacy and safety
of combinations of everolimus
and exemestane in patients with
hormone receptor positive breast
cancer that was refractory to nonsteroidal
aromatase inhibitors.
CLICK HERE to access the bulletin.The above article was sent to subscribers in Pharmacy Daily's issue from 19 Nov 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Nov 13
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.